Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial
Links shared publicly online about this topic.
- 567total visits
Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial
Plexxikon has utilized its proprietary discovery platform to successfully develop a portfolio of clinical and preclinical stage programs in a number of therapeutic areas, including cardio-renal disease, CNS, inflammation, metabolic disease and oncology.
View full resource at plexxikon.com
Tags: Nervous System, Cancer, Skin Cancer, Melanoma, Disease and Condition, Phase 3 Clinical Trial, disease
Most Recently Shared on January 20, 2011 at 2:49 pm By:
Melanoma, metastatic: inhibitor of mutated BRAF improves survival in phase III trial http://bit.ly/hkNVJQ
Advertisement
